Gene Mack, CEO, GAIN Therapeutics, highlights early Phase Ib data showing GT-02287 may enhance neuroprotection across a wider spectrum of Parkinson’s patients regardless of genetic status.

Q2 2025 Management View CEO Jon R. Cohen reported "meaningful progress on several initiatives across the business and added a ...

Tariffs— Shawn Munsell stated, "Under the 10% tariff environment, our exposure without mitigation could approach $8 million ...

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

Furthermore, the Company has been provided an update that its first orders of twenty (20) ElphaPex DG1+ miners are scheduled ...

Discover New Mountain Finance Corporation's Q2 2025 earnings insights, including a stable $0.32 dividend, portfolio updates, refinancing plans, ...

This List includes venture capital firms that invested in companies headquartered in the Greater Bay Area counties of Alameda, Contra Costa, Marin, Monterey, Napa, San Benito, San Francisco, San Mateo ...

How leading retailers use search intelligence to navigate AI overviews, optimize shopping ads, and win market share.

ADM topped Q2 EPS expectations despite softer sales and segment profits, narrowed full-year guidance, and sees biofuel policy ...

Backlog -- Backlog reached a record of nearly $23 billion in Q3 fiscal 2025, up 14% year-over-year; Trailing twelve-month ...

Chris Walker, director of public and external affairs, Advertising Association, offers more info on how adland can play its ...

This was highlighted in an exclusive Gulf Construction interview with a DCT-Abu Dhabi spokesman, who offers an insight into ...